Pfizer has another JAK inhibitor - ritlecitinib - shown to be effective (vs PBO) in alopecia areata in the Phase 2b/3 ALLEGRO trial. Ritlecitinib is also being studied in vitiligo, rheumatoid arthritis, Crohn’s & ulcerative colitis. https://t.co/ccx0eRXuTS https://t.co/fApTP7WaYU